BACKGROUND In the setting of primary percutaneous coronary intervention (PPCI), patients with a concurrent chronic total occlusion (CTO) in a non-infarct related artery (IRA) were recently identified as a high-risk subgroup. It is unclear whether ST-elevation myocardial infarction (STEMI) patients with a CTO in a non-IRA should undergo additional percutaneous coronary intervention of the chronic total occlusion on top of optimal medical therapy shortly after PPCI. Possible beneficial effects include reduction in adverse left ventricular remodeling and preservation of global left ventricular function and improved long term clinical outcome.
METHODS The EXPLORE trial is a global randomized, prospective, multicenter, two-arm trial with blinded evaluation of endpoints. A total of 304 patients were included after successful PPCI for STEMI with a concurrent CTO in a non-IRA and were randomized to either elective PCI of the CTO within 7 days or standard medical treatment. Primary endpoints are left ventricular ejection fraction and left ventricular end-diastolic volume assessed by cardiac Magnetic Resonance Imaging at four months, analyzed by an independent corelab. All events underwent independent monitoring and were adjudicated by an independent critical events committee. Furthermore, all angiographies were reviewed by an independent corelab.
RESULTS In total, 304 STEMI patients with a CTO were included from 07-11-2007 until 30-03-2015 . Data is currently analyzed.
CONCLUSIONS The ongoing EXPLORE trial is the first randomized clinical trial powered to investigate whether recanalization of a chronic total occlusion in a non-infarct related artery after primary percutaneous coronary intervention for ST-elevation myocardial infarction results in a better preserved residual left ventricular ejection fraction, reduced end-diastolic volume and enhanced clinical outcome. BACKGROUND A major determinant of mortality and morbidity is the extent of myocardial necrosis after STEMI, and strategies to limit infarct size may therefore improve prognosis. As recently demonstrated in human studies, pressure-controlled intermittent coronary sinus occlusion (PICSO) may enhance myocardial recovery in acute myocardial infarction. Whether coronary sinus occlusion should be established before reperfusion is unknown.
METHODS In a prospective, controlled study, 28 pigs undergoing 90 minutes of left anterior descending (LAD) coronary artery balloon occlusion followed by reperfusion were randomly assigned to 3 groups: Early PICSO (starting 10 minutes prior to reperfusion, group A, n¼9), Late PICSO (starting 30 minutes post reperfusion, group B, n¼10), or reperfusion only (group C, n¼9). PICSO was administered in an automatic mode for 90 minutes after initiation. Mean PICSO quantity was defined as the sum of the coronary sinus pressure modulation for all PICSO cycles. Infarct size (% left ventricular mass), microvascular obstruction (MVO), and left ventricular function were assessed by cardiac magnetic resonance imaging (MRI) on day 5. VEGF receptor expression was assessed by immunohistochemistry after sacrifice on day 5.
RESULTS
The histologic and MRI group mean values for percent infarct size were numerically lowest in Group A when compared to Group B and Group C, albeit not reaching significance (13.5%AE5.8% vs. 16.6%AE3.6% vs. 16.2%AE4.2% respectively, p¼0.31). The same was true for MVO (3.2%AE3.5% vs. 6.4%AE7.7% vs. 8.8%AE7.1% respectively, p¼0.16). However, left ventricular ejection fraction (LVEF) was greatest in the Early PICSO group (61.0AE7.0% vs. 50.2AE9.8% vs. 52.3AE7.3% respectively, p¼0.02), as was wall thickening (49.7AE15.0 vs. 33.7AE15.1 vs. 39.5AE7.0 respectively, p¼0.045). Compared to control, group A animals had 3-fold greater expression of VEGF-R1 in the myocardial zone remote from the infarct (median [IQR] 19 [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] vs. 9 [6.8-11 .5] vs. 5 [3.5-8] respectively, p¼0.001). Group B animals had 2-fold greater expression of VEGF-R2 in the border zone of the infarct compared to control (5 [3.5-9], 14.5 [9.5-16], 6 [5-12.5 ], respectively). No safety issues were noted.
CONCLUSIONS PICSO was safely applied in a porcine model of LAD infarction. MRI at day 5 showed greater LVEF, better wall thickening, and trends toward smaller infarct size and MVO in animals treated with early PICSO, suggesting a cardioprotective effect of PICSO. In addition, PICSO resulted in an increased VEGF-R1 expression in the remote zone and VEGF-R2 in the border zone indicating, increased neo-angiogenic activity. Large trials are underway to demonstrate the benefits of PICSO in humans. TCT-10 Clinical outcomes following "full-plastic jacket" bioresorbable scaffold implantation Hiroyoshi Kawamoto, 1 Azeem Latib, 1 Neil Ruparelia, 1 Akihito Tanaka, 1 Alessandro Sticchi, 2 Francesco Giannini, 2 Alaide Chieffo, 2 Mauro Carlino, 2 Matteo Montorfano, 2 Antonio Colombo 1 1 EMO GVM Centro Cuore Columbus/San Raffaele Scientific Institute, Milan, Italy; 2 San Raffaele Scientific Institute, Milan, Italy BACKGROUND When performing percutaneous coronary intervention (PCI) for long-diffuse lesions, the best revascularization strategy remains unclear with options including treating most of the vessel length as opposed to a focal approach. A common option is to create a "full-metal jacket (FMJ)". However, FMJ may preclude future surgical revascularization and may be associated with higher events rates at follow-up. The use of bioresorbable scaffolds (BRS) is therefore very attractive by virtue of their full reabsorption 2 to 3 years after implantation. We aimed to investigate the feasibility and updated clinical outcomes following BRS implantation for very long lesions ("full-plastic jacket").
METHODS
We analyzed consecutive patients who underwent PCI with Absorb BRS (Abbott Vascular, Santa Clara, CA) between May 2012 and April 2015. Procedural "full-plastic jacket" (FPJ) was defined as a continuous implantation of BRS with 60mm length or more. During the study period, 290 lesions (196 patients) treated with BRS (total length < 60mm) and 35 lesions (35 patients) treated with FPJ were identified.
RESULTS
Patients treated with FPJ had a higher prevalence of diabetes (40.0% vs. 22.4%, p¼0.03), chronic total occlusion (17.1% vs. 4.5%, p¼0.01), and higher SYNTAX scores (23.5AE13.0 vs. 16.1AE9.5, p<0.001) compared to those with control BRS group (total length < 60mm). The main target vessel in the FPJ group was the LAD (80.0%). The incidence of periprocedural myocardial infarction (as defined by a creatinine kinase (CK) >2 times the upper limit of normal in addition to a CK-MB elevation) was higher in the FPJ group (FPJ 16.1% vs. control BRS group 8.8%: p¼0.20) . The incidence of major adverse cardiac events (defined as a combination of all-cause death, follow-up myocardial infarction and target vessel revascularization) tended to be higher in the FPJ group (FPJ 15.8% vs. control BRS group 9.4%: p¼0.35) at 1-year follow-up. Definite scaffold thrombosis was observed in 1 patient who was treated with a FPJ and stopped clopidogrel at 2 months after PCI. The incidence of target lesion revascularization (per lesion) was significantly higher in the FPJ group (FPJ 12.5% vs. control BRS group 5.0%: p¼0.01).
CONCLUSIONS The incidence of periprocedural MI and TLR was higher in the FPJ group. FPJ treatment for diffuse long lesions appears to be feasible taking into account the greater co-morbidity and lesion complexity in this group.
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Five-year Follow up of the First in Man use of a Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis; A Serial Multi-Imaging Modality Study BACKGROUND The study has ascertained the long term benefits of coronary stenosis treatment with a bioresorbable scaffold eluting everolimus.
METHODS In the ABSORB Cohort B multi-center, single arm trial, 45 patients (B1) and 56 patients (B2) underwent at different time points serial quantitative coronary angiography (QCA), intra vascular ultrasound (IVUS) and optical coherence tomography (OCT). At 5 years 53 patients without Target Lesion Revascularization (TLR) were re-consented to undergo a final serial invasive imaging.
RESULTS Between 6 months/1 year and 5 years angiographic luminal late loss (LLL) remained unchanged; B1 0.14AE19mm vs 0.13AE0.33mm, p¼0.7953, B2 0.23AE0.28mm vs 0.18AE0.32mm, p¼0.5685. When patients with a TLR were included LLL was 0.15AE0.20 mm vs 0.15AE0.24 mm, p¼0.8275 for B1 and 0.30AE0.37 mm vs 0.32AE0.48 mm, p¼0.8204 for B2. For the entire cohort in-scaffold and in-segment binary restenosis was 7.8% (5/64) and 12.5% (8/64), respectively. On IVUS the minimum lumen area (MLA) of B1 decreased from 5.23AE0.97 mm 2 at 6 months to 4.89AE1.81mm 2 at 5 years (p¼0.04) while it remained unchanged in B2 (4.95AE0.91mm 2 at 1 year, 4.84AE1.28 mm 2 at 5 years, p¼0.5). At 5 years the struts were no longer discernable by OCT and IVUS. On OCT MLA in B1 decreased from 4.51AE1.28mm 2 at 6 months to 3.65AE1.39mm 2 at 5years (p¼0.01), while it remained unchanged in B2 (4.35AE1.09mm 2 at 1 year, 4.12AE1.38mm 2 at 5 years, p¼0.24). In the entire Cohort B the 5-year Major Adverse Cardiac Event (MACE) rate was 11.0% without any scaffold thrombosis, definite or probable.
CONCLUSIONS At 5 years implantation of a bioresorbable scaffold resulted in stable lumen dimensions, a low restenosis rate and a low MACE rate.
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